Tumor lysis syndrome: still the Achilles heel of venetoclax in treatment of CLL?

Click to increase image sizeClick to decrease image size

Disclosure statement

MAA is an employee of the Walter and Eliza Hall Institute of Medical Research, which receives milestone and royalty payments related to venetoclax. MAA is recipients of a share in royalty payments paid to the Walter and Eliza Hall Institute of Medical Research. JFS receives research funding from AbbVie, Genentech, Celgene, and Janssen; and is an advisory board member and has received honoraria from AbbVie, Acerta, Celgene, Genentech, Janssen, Roche, Sunesis, and Takeda. MAA has received honoraria from AbbVie, Astrazeneca, Janseen and CSL.